A 7-year-old al­liance be­tween Cel­gene and Ac­celeron is pay­ing off with more promis­ing PhI­II da­ta for lus­pa­ter­cept

Just days af­ter hit­ting its first set of marks in a crit­i­cal­ly im­por­tant Phase III study, Ac­celeron $XL­RN and its part­ners at Cel­gene $CELG say that their prospec­tive block­buster lus­pa­ter­cept has rung all the right bells in a piv­otal study for be­ta tha­lassemia.

Their drug has suc­ceed­ed in the close­ly watched BE­LIEVE study, say in­ves­ti­ga­tors, with a “high­ly sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in the pri­ma­ry end­point of ery­throid re­sponse, which was de­fined as at least a 33% re­duc­tion from base­line in red blood cell (RBC) trans­fu­sion bur­den with a re­duc­tion of at least 2 units dur­ing the pro­to­col-de­fined pe­ri­od of 12 con­sec­u­tive weeks, from week 13 to week 24, com­pared to place­bo.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER